This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Long YM Bio Nightmare Has Ended -- Happily.

FOSTER CITY, Calif. ( TheStreet) -- Gilead Sciences (GILD - Get Report) is buying YM Biosciences (YMI) for $510 million in cash, adding another experimental drug to its growing blood-related cancer portfolio.

The Gilead acquisition values YM Bio at $2.95 per share, or an 81% premium to the stock's closing price Wednesday.

YM Bio's lead drug is CYT387, an oral JAK inhibitor under development as a treatment for myelofibrosis. Gilead intends to begin a phase III study of CYT387 in the second half of 2013, pending the close of the acquisition.

Gilead is known for its HIV and hepatitis C drugs but has also been developing a cancer drug pipeline that receives less attention. The company's lead cancer drug is idealisib (formerly GS-1101), a PI3K inhibitor currently in five phase III studies for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. A second Gilead drug is in mid-stage studies for a variety of cancer indications.

The purchase of YM Bio is a happy ending to what's been a long and frustrating story for the company's shareholders. Data from mid-stage studies have long suggested CYT387 could be a superior treatment for myelofibrosis compared to Incyte's (INCY - Get Report) Jakafi. Unfortunately, investors never seemed to give YM Bio much credit for CYT387.

Until Wednesday, YM Bio's management team had done little to bolster the credibility of CYT387 by dragging its feet on moving the drug into phase III studies.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GILD $103.70 0.00%
INCY $107.34 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs